RGNX
Price
$7.85
Change
-$0.05 (-0.63%)
Updated
Aug 8 closing price
Capitalization
396.54M
87 days until earnings call
STRO
Price
$0.80
Change
-$0.00 (-0.00%)
Updated
Aug 8 closing price
Capitalization
67.77M
87 days until earnings call
Interact to see
Advertisement

RGNX vs STRO

Header iconRGNX vs STRO Comparison
Open Charts RGNX vs STROBanner chart's image
REGENXBIO
Price$7.85
Change-$0.05 (-0.63%)
Volume$637.52K
Capitalization396.54M
Sutro Biopharma
Price$0.80
Change-$0.00 (-0.00%)
Volume$311.24K
Capitalization67.77M
RGNX vs STRO Comparison Chart in %
Loading...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGNX vs. STRO commentary
Aug 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Buy and STRO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 10, 2025
Stock price -- (RGNX: $7.85 vs. STRO: $0.80)
Brand notoriety: RGNX and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 80% vs. STRO: 36%
Market capitalization -- RGNX: $396.54M vs. STRO: $67.77M
RGNX [@Biotechnology] is valued at $396.54M. STRO’s [@Biotechnology] market capitalization is $67.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, both RGNX and STRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 3 TA indicator(s) are bullish while STRO’s TA Score has 4 bullish TA indicator(s).

  • RGNX’s TA Score: 3 bullish, 5 bearish.
  • STRO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both RGNX and STRO are a bad buy in the short-term.

Price Growth

RGNX (@Biotechnology) experienced а -4.15% price change this week, while STRO (@Biotechnology) price change was -0.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.25%. For the same industry, the average monthly price growth was +6.85%, and the average quarterly price growth was +13.24%.

Reported Earning Dates

RGNX is expected to report earnings on Nov 05, 2025.

STRO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($397M) has a higher market cap than STRO($67.8M). RGNX YTD gains are higher at: 1.552 vs. STRO (-56.391). RGNX has higher annual earnings (EBITDA): -122.44M vs. STRO (-203.18M). RGNX has more cash in the bank: 268M vs. STRO (249M). STRO has less debt than RGNX: STRO (21.4M) vs RGNX (79.8M). RGNX has higher revenues than STRO: RGNX (157M) vs STRO (66.4M).
RGNXSTRORGNX / STRO
Capitalization397M67.8M586%
EBITDA-122.44M-203.18M60%
Gain YTD1.552-56.391-3%
P/E RatioN/AN/A-
Revenue157M66.4M236%
Total Cash268M249M108%
Total Debt79.8M21.4M373%
FUNDAMENTALS RATINGS
RGNX vs STRO: Fundamental Ratings
RGNX
STRO
OUTLOOK RATING
1..100
5837
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6365
P/E GROWTH RATING
1..100
24100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STRO's Valuation (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for RGNX (73) in the Biotechnology industry. This means that STRO’s stock grew somewhat faster than RGNX’s over the last 12 months.

STRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RGNX (100) in the Biotechnology industry. This means that STRO’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (97) in the Biotechnology industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew similarly to STRO’s over the last 12 months.

RGNX's Price Growth Rating (63) in the Biotechnology industry is in the same range as STRO (65) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew similarly to STRO’s over the last 12 months.

RGNX's P/E Growth Rating (24) in the Biotechnology industry is significantly better than the same rating for STRO (100) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew significantly faster than STRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXSTRO
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 18 days ago
76%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 13 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BRRLY12.390.19
+1.52%
Barry Callebaut AG
GBBYF0.17N/A
N/A
Goodbaby International Holdings Ltd
NDTP0.06N/A
N/A
NDT Pharmaceuticals Inc.
ARBFF24.92N/A
N/A
ARB Corp., Ltd.
CIHKY32.16-0.18
-0.56%
China Merchants Bank Co., Ltd.

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with ALGS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then ALGS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
+0.30%
ALGS - STRO
44%
Loosely correlated
-5.41%
PDSB - STRO
39%
Loosely correlated
-0.89%
BEAM - STRO
38%
Loosely correlated
-1.34%
FATE - STRO
38%
Loosely correlated
-5.99%
RGNX - STRO
38%
Loosely correlated
-0.63%
More